• Consensus Rating: Buy
  • Consensus Price Target: $3.06
  • Forecasted Upside: 104.68%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$1.50
▼ -0.075 (-4.78%)

This chart shows the closing price for BDSX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Biodesix Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BDSX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BDSX

Analyst Price Target is $3.06
▲ +104.68% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Biodesix in the last 3 months. The average price target is $3.06, with a high forecast of $3.50 and a low forecast of $2.80. The average price target represents a 104.68% upside from the last price of $1.50.

This chart shows the closing price for BDSX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 5 investment analysts is to buy stock in Biodesix. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/2/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/30/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/29/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/28/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/26/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/24/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/23/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/23/2024

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
9/16/2024ScotiabankInitiated CoverageSector Outperform$3.00
7/26/2024Craig HallumInitiated CoverageBuy$3.00
5/13/2024TD CowenInitiated CoverageBuy$2.80
5/3/2024Lake Street CapitalInitiated CoverageBuy$3.00
3/4/2024Canaccord Genuity GroupReiterated RatingBuy ➝ Buy$3.50
12/7/2023Canaccord Genuity GroupReiterated RatingBuy ➝ Buy$3.50
11/15/2023WedbushReiterated RatingOutperform
11/8/2023William BlairReiterated RatingOutperform
11/23/2022William BlairReiterated RatingOutperform
5/12/2022Canaccord Genuity GroupLower Target$10.00 ➝ $7.00
4/20/2022CowenInitiated CoverageOutperform
4/20/2022CowenInitiated CoverageOutperform
4/14/2022BTIG ResearchReiterated RatingBuy$17.00 ➝ $10.00
2/15/2022Canaccord Genuity GroupLower TargetBuy ➝ Buy$22.00 ➝ $18.00
11/17/2021Morgan StanleyDowngradeOverweight ➝ Equal Weight$21.00 ➝ $11.00
9/23/2021BTIG ResearchLower TargetBuy$28.00 ➝ $22.00
5/12/2021Morgan StanleyLower TargetOverweight$25.00 ➝ $23.00
3/18/2021Morgan StanleyBoost TargetOverweight$20.00 ➝ $25.00
11/23/2020William BlairInitiated CoverageOutperform
11/23/2020Morgan StanleyInitiated CoverageOverweight$20.00
11/23/2020BTIG ResearchInitiated CoverageBuy$22.00
(Data available from 12/23/2019 forward)

News Sentiment Rating

0.54 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 7 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/27/2024
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/26/2024
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/26/2024
  • 4 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
8/25/2024
  • 4 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/24/2024
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/24/2024
  • 5 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/23/2024
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/23/2024

Current Sentiment

  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Biodesix logo
Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and NGS, and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.
Read More

Today's Range

Now: $1.50
Low: $1.49
High: $1.57

50 Day Range

MA: $1.43
Low: $1.19
High: $1.70

52 Week Range

Now: $1.50
Low: $1.11
High: $2.21

Volume

72,554 shs

Average Volume

213,325 shs

Market Capitalization

$217.47 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.14

Frequently Asked Questions

What sell-side analysts currently cover shares of Biodesix?

The following Wall Street analysts have issued stock ratings on Biodesix in the last twelve months: Canaccord Genuity Group Inc., Craig Hallum, Lake Street Capital, Scotiabank, and TD Cowen.
View the latest analyst ratings for BDSX.

What is the current price target for Biodesix?

0 Wall Street analysts have set twelve-month price targets for Biodesix in the last year. Their average twelve-month price target is $3.06, suggesting a possible upside of 104.7%. Canaccord Genuity Group Inc. has the highest price target set, predicting BDSX will reach $3.50 in the next twelve months. TD Cowen has the lowest price target set, forecasting a price of $2.80 for Biodesix in the next year.
View the latest price targets for BDSX.

What is the current consensus analyst rating for Biodesix?

Biodesix currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BDSX will outperform the market and that investors should add to their positions of Biodesix.
View the latest ratings for BDSX.

What other companies compete with Biodesix?

Other companies that are similar to Biodesix include Fulgent Genetics, InnovAge, Auna, Celcuity and DocGo. Learn More about companies similar to Biodesix.

How do I contact Biodesix's investor relations team?

The company's listed phone number is 303-417-0500 and its investor relations email address is [email protected]. The official website for Biodesix is www.biodesix.com. Learn More about contacing Biodesix investor relations.